Drug intelligence / Profile preview

GXIPC1

Development stage: Unknown
Lead developer: Gwo Xi Stem Cell Applied Technology
Modality: Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

GXIPC1 is an allogeneic adipose-derived mesenchymal stem cell therapy developed for the treatment of type 1 diabetes. The product consists of stem cells collected from healthy donors and is designed to regulate blood sugar levels and protect pancreatic islets. Preclinical studies have demonstrated its potential to improve diabetic conditions by controlling blood glucose, and it has advanced into Phase 1 clinical trials to evaluate safety in patients with type 1 diabetes mellitus. The therapy is administered intravenously[5][2][3][1].

Beyond the preview

Go deeper on GXIPC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GXIPC1.

Explore the full profile